Skip to main content
QMSQMS
QMS
  • Welcome to your QMS
  • Quality Manual
  • Procedures
  • Records
  • Legit.Health Plus Version 1.1.0.0
    • Index
    • Overview and Device Description
    • Information provided by the Manufacturer
    • Design and Manufacturing Information
      • R-TF-012-019 SOUPs
      • R-TF-012-028 Software Requirement Specification
      • R-TF-012-029 Software Architecture Description
      • R-TF-012-030 Software Configuration Management Plan
      • R-TF-012-031 Product requirements specification
      • R-TF-012-037 Labeling and IFU Requirements
      • R-TF-012-040 Documentation level FDA
      • R-TF-012-041 Software Classification 62304
      • R-TF-012-043 Traceability Matrix
      • Review meetings
        • Phase 1: Product Design Review
        • Phase 2: Software Design Review
        • Phase 3: Software Development Review (Release Candidate)
        • Phase 4: Software Verification Review
        • Phase 5: Product Validation Review
    • GSPR
    • Benefit-Risk Analysis and Risk Management
    • Product Verification and Validation
    • Post-Market Surveillance
  • Legit.Health Plus Version 1.1.0.1
  • Legit.Health Utilities
  • Licenses and accreditations
  • Applicable Standards and Regulations
  • Pricing
  • Public tenders
  • Legit.Health Plus Version 1.1.0.0
  • Design and Manufacturing Information
  • Review meetings
  • Phase 2: Software Design Review

Phase 2: Software Design Review

Process Overview​

The purpose of the Software Design review (Phase 2) is to ensure that all outputs of the Software Design phase satisfy the criteria required to proceed to Phase 3 (Software Development). This review validates that software requirements, architecture, test plans, and related procedural documents are complete and ready for implementation.

According to GP-012, Phase 2 establishes the input data for development and initiates parallel procedures for risk management, clinical evaluation, cybersecurity, AI/ML development, and usability.

General Information​

Information
Device nameLegit.Health Plus (hereinafter, the device)
Model and typeNA
Version1.1.0.0
Basic UDI-DI8437025550LegitCADx6X
Certificate number (if available)MDR 792790
EMDN code(s)Z12040192 (General medicine diagnosis and monitoring instruments - Medical device software)
GMDN code65975
EU MDR 2017/745Class IIb
EU MDR Classification ruleRule 11
Novel product (True/False)TRUE
Novel related clinical procedure (True/False)TRUE
SRNES-MF-000025345

Project Information​

  • Project title: Legit.Health Plus Version 1.1.0.0
  • Project manager: JD-007 (Technical Manager)
  • Review date: 2025-12-01
  • Reviewers: JD-001 (General Manager), JD-003 (Design & Development Manager), JD-007 (Technical Manager), JD-004 (Quality Manager & PRRC)

Planning​

PhaseObjectDone
Phase 1 Product Design ReviewEstablish input data✓
Phase 2 Software Design ReviewSRs, Architectural Design and UI Prototypes✓
Phase 3 Software DevelopmentCoding, integration and test plan
Phase 4 Software Verification ReviewSoftware version verified and residual anomalies
Phase 5 Product Validation ReviewValidation activities, Technical Documentation and DHF

Previous Reserves​

All reserves from Phase 1 have been addressed and closed.

N°Issue from Phase 1ResolutionStatus
-No reserves--

Software Design Outputs Checklist​

Software Planning and Specification Documents​

DocumentStatusReferenceComments
Software Development Plan✓R-TF-012-023 Software Development PlanComplete, includes methodology and planning
Software Requirements Specification (SRS)✓R-TF-012-028 Software Requirement SpecificationAll SRS documented and traceable to PRs
Software Architecture Description✓R-TF-012-029 Software Architecture DescriptionArchitecture defined with component interfaces
Software Configuration Management Plan✓R-TF-012-030 Software Configuration Management PlanVersion control and branching strategy defined
Software Test Plan✓R-TF-012-033 Software Test PlanTest strategy and test cases defined
Software Test Description✓R-TF-012-034 Software Test DescriptionDetailed test procedures documented
Traceability Matrix (draft)✓R-TF-012-043 Traceability MatrixPR → SRS → Test Cases traceability established
SOUP Components List✓R-TF-012-019 SOUPsAll SOUP components identified and assessed

Software Requirements Quality​

CriterionStatusComments
Requirements are complete✓All functional and non-functional requirements documented
Requirements are understandable✓Clear, unambiguous language used
Requirements are traceable to Product Requirements✓Traceability matrix established (PR → SRS)
Requirements are testable✓Test criteria defined for each requirement
Requirements are uniquely identified✓Each SRS has unique identifier (GitHub Issues)
Requirements include user interface requirements✓UI/UX requirements documented
Requirements include cybersecurity requirements✓Security requirements traceable to Security Risks
Requirements include risk control measures✓Safety risk controls implemented in software documented

Parallel Procedures Initiated (Other Procedures Kickoff)​

According to GP-012, Phase 2 initiates parallel procedures. Important: AI/ML Development (GP-028) is unique in that it must be fully completed during Phase 2, unlike other procedures that continue through subsequent phases. This ensures the software development team receives complete, validated AI/ML components for integration in Phase 3.

ProcedurePlan DocumentStatusResponsibleCompletion Phase
Risk Management (GP-013)R-TF-013-001 Risk Management Plan✓JD-003, JD-004Phase 5
Risk Management RecordR-TF-013-002 Risk Management Record✓JD-003, JD-004Phase 5
Clinical Evaluation (GP-015)R-TF-015-008 Clinical Evaluation Plan✓JD-018Phase 5
Cybersecurity (GP-030)R-TF-030-002 Cybersecurity Plan✓JD-007Phase 5
Cybersecurity Risk MatrixR-TF-030-003 Security Risk Matrix✓JD-007Phase 5
Usability (GP-025)R-TF-025-001 Usability plan✓JD-003Phase 5

AI/ML Development Complete Package (GP-028)​

Critical: AI/ML development must be fully completed at the end of Phase 2, before Phase 3 begins. All AI/ML outputs, including algorithms, validation reports, and documentation, must be delivered to the software development team as a complete, verified package.

DocumentStatusReferenceResponsibleComments
AI/ML Description✓R-TF-028-001 AI/ML DescriptionJD-017Algorithm specifications defined
AI/ML Development Plan✓R-TF-028-002 AI/ML Development PlanJD-017Development methodology and resources planned
Data Collection✓R-TF-028-003 Data Collection InstructionsJD-017Data acquisition protocol complete
Data Annotation✓R-TF-028-004 Data Annotation InstructionsJD-017Annotation procedures complete
AI/ML Design Checks✓R-TF-028-009 AI/ML Design ChecksJD-017Design phase verification complete
AI/ML Development Report✓R-TF-028-005 AI/ML Development ReportJD-017Complete development and validation documentation
AI/ML Release Report✓R-TF-028-006 AI/ML Release ReportJD-017Integration specifications for software team
AI/ML V&V Checks✓R-TF-028-010 AI/ML V&V ChecksJD-017Verification and validation checklist complete
AI Risk Matrix✓R-TF-028-011 AI Risk MatrixJD-017AI-specific risks identified and assessed
Algorithm Package✓SDK/Models ready for integrationJD-017Validated algorithms ready for software development team

AI/ML Completion Confirmation:

  • All AI/ML development activities complete ✓
  • All algorithms validated and tested ✓
  • Complete package delivered to software development team ✓
  • Software team can begin Phase 3 integration ✓

Validation Plans​

Plan DocumentStatusReferenceResponsible
Software Test Plan (Verification)✓R-TF-012-033 Software Test PlanJD-007
Usability Plan✓R-TF-025-001 Usability planJD-003
Clinical Evaluation Plan✓R-TF-015-008 Clinical Evaluation PlanJD-018

IEC 62304 Compliance Review​

Planning (Class B Requirements)​

RequirementStatusEvidence
5.1 Software Development Plan established✓R-TF-012-023 Software Development Plan
5.1.6 Software Verification planning✓R-TF-012-033 Software Test Plan
5.1.9 Configuration Management documented✓R-TF-012-030 Software Configuration Management Plan

Requirements Analysis (Class B)​

RequirementStatusEvidence
5.2 Software Requirements defined and documented✓R-TF-012-028 Software Requirement Specification
5.2.3 Risk control measures in software✓R-TF-013-002 Risk Management Record
Requirements complete and verifiable✓All SRS are testable and traceable

Architecture (Class B)​

RequirementStatusEvidence
5.3.1 Software Architecture documented✓R-TF-012-029 Software Architecture Description
5.3.2 Interfaces between software elements✓Component interfaces defined in architecture
5.3.3 SOUP functional requirements specified✓R-TF-012-019 SOUPs
5.3.4 SOUP hardware/software requirements✓SOUP prerequisites documented
5.3.6 Architecture verification✓Architecture reviewed for consistency and feasibility

Risk Management Integration (Class B)​

RequirementStatusEvidence
7.1.1 Hazardous software elements identified✓R-TF-013-002 Risk Management Record
7.1.2-7.1.5 Software risk analysis performed✓Potential causes and sequences documented in Risk Management Record
7.2 Risk control measures documented✓Controls traceable to SRS and implementation

IEC 81001 (Cybersecurity) Compliance Review​

RequirementStatusEvidence
Security requirements defined✓R-TF-030-003 Security Risk Matrix
Threat model established✓R-TF-030-002 Cybersecurity Plan
Security controls defined✓Security controls traceable to threats and SRS

Design History File (DHF) Status​

ItemStatusComments
DHF structure established✓All documentation organized and accessible
All Phase 2 outputs documented✓Complete documentation available
Document version control implemented✓Git-based version control active
Traceability established✓PR → SRS → Architecture → Test Cases

Reserves and Pending Actions​

N°Issue / Action RequiredOwnerTargeted DateStatus
-No reserves identified at this phase---

Conclusion​

Review Outcome: The Phase 2 Software Design review has been successfully completed.

Assessment:

  • All software design outputs are complete, available, and relevant
  • Software Requirements Specification (SRS) is comprehensive, traceable, and testable
  • Software architecture is well-defined with clear component interfaces
  • All required plans (verification, risk management, clinical, cybersecurity, AI/ML, usability) have been established
  • SOUP components have been identified and assessed
  • IEC 62304 Class B requirements are satisfied
  • IEC 81001 cybersecurity requirements are addressed
  • Traceability from Product Requirements to Software Requirements is established
  • Design History File is properly organized and up-to-date

Decision: The project is approved to proceed to Phase 3: Software Development.

Next Steps:

  • Begin agile iterative development sprints
  • Implement software according to SRS and architecture
  • Continue parallel procedures (risk management, clinical, cybersecurity, AI/ML, usability)
  • Maintain traceability throughout implementation
  • Prepare for Phase 3 release candidate review

Approved by:

Signature meaning

The signatures for the approval process of this document can be found in the verified commits at the repository for the QMS. As a reference, the team members who are expected to participate in this document and their roles in the approval process, as defined in Annex I Responsibility Matrix of the GP-001, are:

  • Author: Team members involved
  • Reviewer: JD-003, JD-004
  • Approver: JD-001
Previous
Phase 1: Product Design Review
Next
Phase 3: Software Development Review (Release Candidate)
  • Process Overview
  • General Information
  • Project Information
  • Planning
  • Previous Reserves
  • Software Design Outputs Checklist
    • Software Planning and Specification Documents
    • Software Requirements Quality
    • Parallel Procedures Initiated (Other Procedures Kickoff)
    • AI/ML Development Complete Package (GP-028)
    • Validation Plans
  • IEC 62304 Compliance Review
    • Planning (Class B Requirements)
    • Requirements Analysis (Class B)
    • Architecture (Class B)
    • Risk Management Integration (Class B)
  • IEC 81001 (Cybersecurity) Compliance Review
  • Design History File (DHF) Status
  • Reserves and Pending Actions
  • Conclusion
All the information contained in this QMS is confidential. The recipient agrees not to transmit or reproduce the information, neither by himself nor by third parties, through whichever means, without obtaining the prior written permission of Legit.Health (AI Labs Group S.L.)